SARS-CoV-2 Sarcopenia: An Update

Sarcopenia, characterized by the loss of muscle mass and strength, has become a critical concern during the COVID-19 pandemic, influencing patient outcomes such as extended hospital stays, higher mortality, and slower recovery.Factors like chronic inflammation, immune dysfunction, respiratory muscle impairment, and sarcopenic dysphagia contribute to these poor outcomes.COVID-19 exacerbates sarcopenia through mechanisms such as cytokine storms, hormonal imbalances, hypoxia, and mitochondrial dysfunction, all of which accelerate muscle degradation and functional decline.Additionally, the pandemic's impact on physical activity, nutritional status and mental welfare has further worsened sarcopenia, especially in older adults and vulnerable populations.The relationship between COVID-19 and sarcopenia is bidirectional, where muscle loss compromises the immune response, increasing the risk of severe infection, while COVID-19 itself accelerates muscle wasting through inflammation, physical inactivity, malnutrition, and other factors.This interplay heightens vulnerability, prolongs recovery, and worsens overall health outcomes, emphasizing for effective management strategies.Addressing sarcopenia through tailored exercise programs and nutritional interventions is vital for improving long-term recovery and reducing the pandemic's lasting health effects.